TCMDTactile Systems Technology, Inc.
Is the price fair?
Neither cheap nor expensive: nothing decisive, though cheap against its own history.
Priced for ~6% a year FCF growth. Roughly in line with its three-year revenue growth of 10% a year.
Cheap vs its own history: P/E 21.9 vs a 81.5 median over 27 quarters (−73% vs median).
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What TCMD's price assumes
Tactile Systems Technology, Inc. trades at 21.9× earnings against 28.1× for the median Medical Devices name, cheaper than its own group.
Trailing P/E · Medical Devices median 28.1 · cheaper than the typical name in its group
- Price / sales
- 1.96
Price / sales · as of 2026-Q2
- Free cash flow yield
- 5.0%
Free cash flow yield · Medical Devices median 4.0%
- Growth the price implies
- +5.6%
Growth the price implies · The price pays for +5.6% free cash flow growth a year for a decade; the business has delivered +16% a year over the last three.
Details›
- Price / bookas of 2026-Q2
- 3.06
- EV / EBITas of 2026-Q2
- 17.6
- EV / salesas of 2026-Q2
- 1.76
- Healthcare median P/E503 names
- 27.9
- Medical Devices median P/E64 names
- 28.1
- Free cash flow, trailing twelve months
- $27M
- Market capitalisation22.7 million shares, counted Aug 6, 2026
- $536M
- 3-year revenue growth
- +9.6%
- 3-year free cash flow growth
- +16%
| Method | Per share |
|---|---|
| What its own history would imply | not meaningful, 21.9× today against a 81.5× median |
| 52-week range | $14.95 – $33.05 |
| Today | $23.64 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
What is it worth?
Today's price against what its own multiples, its cash flow and your growth assumption say it is worth.
Against its own past
Its multiples now against their own history, and how much of the price move came from earnings rather than the multiple.